Brokerages expect that AxoGen, Inc (NASDAQ:AXGN) will report earnings of ($0.14) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for AxoGen’s earnings, with estimates ranging from ($0.19) to ($0.11). AxoGen posted earnings of ($0.11) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 27.3%. The firm is scheduled to issue its next quarterly earnings results on Monday, April 29th.
On average, analysts expect that AxoGen will report full year earnings of ($0.35) per share for the current year, with EPS estimates ranging from ($0.43) to ($0.22). For the next year, analysts anticipate that the company will post earnings of ($0.01) per share, with EPS estimates ranging from ($0.08) to $0.06. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow AxoGen.
AxoGen (NASDAQ:AXGN) last released its earnings results on Tuesday, February 26th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.02. The company had revenue of $23.40 million for the quarter, compared to analyst estimates of $23.40 million. AxoGen had a negative net margin of 26.68% and a negative return on equity of 15.77%. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.07) EPS.
A number of equities research analysts have commented on AXGN shares. BidaskClub downgraded shares of AxoGen from a “buy” rating to a “hold” rating in a research report on Thursday. ValuEngine downgraded shares of AxoGen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $43.00 price objective on shares of AxoGen in a research report on Wednesday, December 19th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. AxoGen presently has an average rating of “Buy” and an average target price of $42.25.
Several large investors have recently made changes to their positions in AXGN. Bank of New York Mellon Corp increased its position in shares of AxoGen by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 903,086 shares of the medical equipment provider’s stock valued at $45,380,000 after purchasing an additional 25,748 shares during the last quarter. Bank of Montreal Can increased its position in shares of AxoGen by 108.6% in the 3rd quarter. Bank of Montreal Can now owns 7,482 shares of the medical equipment provider’s stock valued at $276,000 after purchasing an additional 3,895 shares during the last quarter. First Trust Advisors LP increased its position in shares of AxoGen by 2.4% in the 3rd quarter. First Trust Advisors LP now owns 109,142 shares of the medical equipment provider’s stock valued at $4,022,000 after purchasing an additional 2,586 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of AxoGen by 14.0% in the 3rd quarter. Wells Fargo & Company MN now owns 880,794 shares of the medical equipment provider’s stock valued at $32,457,000 after purchasing an additional 108,372 shares during the last quarter. Finally, WINTON GROUP Ltd increased its position in shares of AxoGen by 22.0% in the 3rd quarter. WINTON GROUP Ltd now owns 17,410 shares of the medical equipment provider’s stock valued at $642,000 after purchasing an additional 3,134 shares during the last quarter. 90.51% of the stock is currently owned by institutional investors.
AxoGen stock opened at $19.76 on Tuesday. The company has a market cap of $775.69 million, a price-to-earnings ratio of -36.59 and a beta of 0.16. AxoGen has a 52-week low of $14.13 and a 52-week high of $56.85.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Featured Article: Are all No-Load Funds Equal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.